Identifying YJU2 as A Potential Drug Target for Disulfide-Bond Formation and Cellular Processes

Target Name: YJU2

NCBI ID: G55702

YJU2

Identifying YJU2 as A Potential Drug Target for Disulfide-Bond Formation and Cellular Processes

YJU2 (CCDC94) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the YJC-associated protein (YJC) family, which is known for their role in cell signaling and development. YJU2 has been identified as a potential drug target (or biomarker) due to its unique structure and the involvement of several disease-related pathways.

The YJC family of proteins is characterized by a characteristic domain that includes a heparan sulfate-containing core and a variable region that includes several conserved motifs, such as a zinc finger, a transmembrane domain, and a carboxy-terminal domain. The YJU2 protein is similar to other members of the YJC family in that it contains a conserved heparan sulfate-containing core and a variable region that includes several conserved motifs.

One of the key features of YJU2 is its unique structure. The protein has a molecular weight of approximately 110 kDa and a calculated pI of approximately 8.0. This indicates that YJU2 is a small protein that is expressed in a variety of tissues and cells at relatively low levels. The protein is also capable of forming a disulfide bond, which is a common structural feature of proteins that plays a role in protein-protein interactions and may be involved in the regulation of cellular processes.

In addition to its unique structure, YJU2 is also involved in several disease-related pathways. For example, the protein has been shown to be involved in the regulation of cell signaling pathways, including the TGF-β pathway and the Wnt pathway. It has also been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the reasons why YJU2 has been identified as a potential drug target is its involvement in several disease-related pathways. For example, the TGF-β pathway is involved in the regulation of cell proliferation and has been implicated in the development of many diseases, including cancer. YJU2 has been shown to play a role in the regulation of TGF-β signaling, which suggests that it may be a useful target for drugs that are designed to inhibit TGF-β signaling.

In addition to its involvement in TGF-β signaling, YJU2 has also been shown to be involved in the regulation of several other signaling pathways, including the Wnt pathway. The Wnt pathway is involved in the regulation of cell growth and has been implicated in the development of many diseases, including cancer. YJU2 has been shown to play a role in the regulation of Wnt signaling, which suggests that it may be a useful target for drugs that are designed to inhibit Wnt signaling.

Another potential mechanism by which YJU2 may be targeted by drugs is its role in the regulation of cellular processes that are associated with aging and age-related diseases. YJU2 has been shown to play a role in the regulation of cellular processes that are associated with aging, such as the production of reactive oxygen species (ROS) and the regulation of cellular senescence. These processes are thought to be involved in the development of many age-related diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, YJU2 is a unique protein that is expressed in various tissues throughout the body and has been shown to be involved in several disease-related pathways. Its conserved structure and ability to form disulfide bonds suggest that it may be a useful target for drugs that are designed to inhibit signaling pathways that are involved in the development and progression of many diseases. Further research is needed to fully understand the role of YJU2 in

Protein Name: YJU2 Splicing Factor Homolog

Functions: Part of the spliceosome which catalyzes two sequential transesterification reactions, first the excision of the non-coding intron from pre-mRNA and then the ligation of the coding exons to form the mature mRNA (PubMed:29301961). Plays a role in stabilizing the structure of the spliceosome catalytic core and docking of the branch helix into the active site, producing 5'-exon and lariat intron-3'-intermediates (By similarity). May protect cells from TP53-dependent apoptosis upon dsDNA break damage through association with PRP19-CD5L complex (PubMed:22952453)

The "YJU2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YJU2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets